Kyowa Kirin has decided to discontinue its eczema drug, rocatinlimab, after a safety review revealed concerning new findings. The drug, which was previously positioned as a potential competitor to the established treatment Dupixent, has now been linked to the onset of a specific type of skin cancer, Kaposi sarcoma. This decision comes just one month after Amgen similarly halted its development of rocatinlimab, underscoring the growing safety concerns surrounding this class of therapies.
The implications of this development extend beyond Kyowa Kirin, as it raises critical questions about the safety profiles of emerging eczema treatments. With regulatory scrutiny intensifying, companies in the dermatological space must now reassess their clinical trial designs and risk management strategies. The abandonment of rocatinlimab serves as a cautionary tale for the industry, highlighting the necessity for robust safety evaluations in the race to bring innovative therapies to market.
Open the full market picture for your next decision →
